Pay in 4 interest-free payments of $5.67 Learn more
Ships within 48 hours · Estimated delivery Aug 11 - Aug 16
Thromb Res
Female sexual desire disorder (clinical) PT-141 FDA-approved for HSDD in premenopausal women with defined efficacy from Phase 3 pivotal trials Melanocortin receptor pharmacology research Melanotan-2 Non-selective agonist profile allows study of MC1R through MC5R activation and multi-system melanocortin signaling Sexual function with regulatory backing PT-141 Only melanocortin-based sexual function treatment with FDA approval and standardized prescription dosing Melanogenesis and tanning research Melanotan-2 Higher MC1R agonist activity produces more robust melanogenesis than PT-141, which was optimized away from tanning effects Continue Your Research Get comparison updates We publish new head-to-head comparisons regularly
E.ZuckermanM
This Retatrutide dosing calc feature removes the need for mental arithmetic between mL and units, a common source of error in a laboratory setting
